Objective: To determine whether elevated homocysteine levels precede the development of preeclampsia.
Methods: Study subjects were selected from a population-based cohort of 1049 nulliparous women from whom serum was collected for Down syndrome screening at 16 weeks' gestation. For 34 women who developed preeclampsia, 68 control women were chosen who remained normotensive. Homocysteine was analyzed by high-performance liquid chromatography and fluorescence detection. The sample size allowed detection of a 1.25-μmol/L difference at a significance level of .05 and the power of .81.
Results: At 16 weeks' gestation, concentrations (mean, 95% confidence interval) of homocysteine in women who developed preeclampsia, 6.99 (6.42, 7.55) μmol/L, were similar to those who remained normotensive, 6.91 (6.45, 7.34) μmol/L.
Conclusion: Significant changes in homocysteine metabolism did not predate the appearance of clinical preeclampsia.
Elevated concentrations of homocysteine have been associated with increased risk of vascular disease.1 The vascular effects of hyperhomocysteinemia have been proposed to include endothelial cell injury and thrombus formation.2 As endothelial cell dysfunction and increased platelet aggregation are characteristic features of preeclampsia,3 a hypothesis has been presented that hyperhomocysteinemia may be associated with this process.4 Earlier findings of elevated plasma homocysteine levels in pregnant women with clinically evident preeclampsia4–6 support this hypothesis. Increased homocysteine concentration in pregnancy may advance endothelial dysfunction in preeclampsia by promoting oxidative stress.1
An interesting question is whether changes in homocysteine metabolism occur before the appearance of clinically evident preeclampsia. Such a finding might demonstrate a value for homocysteine determinations in prediction of preeclampsia. We are aware only of one report claiming that women with elevated homocysteine levels at midtrimester are at increased risk of developing preeclampsia.7 We report a population-based study on nulliparous women participating in a Down syndrome screening program for whom serum homocysteine levels were determined at 16 weeks' gestation. Women who later developed preeclampsia were compared with a control group who remained normotensive.
Homocysteine levels at 16 weeks were not different between women who subsequently developed preeclampsia and those who remained normotensive.
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland.
Address reprint requests to: Timo Laatikainen, MD, PhD, Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Sofianlehdonkatu 5 A, Helsinki, FIN-00610, Finland. E-mail: email@example.com
This work was supported by a grant from Helsinki University Central Hospital.
Received June 20, 2000. Received in revised form October 11, 2000. Accepted October 26, 2000.
Materials and Methods
Details of the population-based cohort studied here were presented previously.8 In short, the cohort was 1049 pregnant nulliparas who participated between January 2, 1996, and August 14, 1996, in the Down screening program at 16 weeks' gestation. Clinical data including blood pressure (BP) values and measurement of urine protein at each trimester were collected from the medical records at the maternity care units and the Helsinki University Hospitals, responsible for maternity care and deliveries in this area. After excluding women with twin pregnancies, spontaneous abortions, insulin-dependent diabetes, and those with missing or incomplete data, 917 women remained eligible for the study. Of them, 94 remained normotensive, 34 developed preeclampsia, and 54 developed gestational hypertension. Chronic hypertension was present in 35, and superimposed preeclampsia was diagnosed in five. In the present study, all 34 women with preeclampsia were included, and as controls for each we chose two subsequent women who attended the Down screening program and remained normotensive. Fourteen of the 68 controls and seven of 34 women in the preeclampsia group had class A diabetes.
Preeclampsia was diagnosed if BP higher than 140/90 mmHg was confirmed by two measurements (in the sitting position) at 6 or more hours apart or a sustained rise of 30 mmHg in systolic and 15 mmHg in diastolic BP, and proteinuria of 300 mg or more per day after 20 weeks' gestation was found in previously normotensive women. The criteria for gestational hypertension were similar to those for preeclampsia except proteinuria. Superimposed preeclampsia was diagnosed if preeclampsia occurred in women who already had chronic hypertension (BP at least 140/90 mmHg). Assay for total homocysteine (including homocysteine-cysteine, mixed disulfides, and protein-bound homocysteine) was performed using high-performance liquid chromatography and fluorescence detection as described in detail previously.6
Student t test and Fisher exact test were used in statistical comparisons and P < .05 was considered statistically significant. Before commencing the study, we calculated the sample size as follows: To detect a 1.25-μmol/L difference in the homocysteine level with a significance level of .05 and with a standard deviation (SD) of 1.75 (based on our previous experience), a minimum of 30 cases and 30 controls would be needed for a power level of greater than .80.
Demographic data on women in the preeclampsia and control groups are given in Table 1. Figure 1 shows that the distribution of serum homocysteine levels was similar when preeclampsia and control groups were compared. At 16 weeks' gestation the mean values ± SD [95% confidence interval (CI)] were 6.99 ± 1.56 (6.4, 7.5) μmol/L and 6.91 ± 1.76 (6.45, 7.34) μmol/L, respectively, without any significant difference between groups (P = 0.83). The upper 25th percentile limit of homocysteine values in the control group was 7.7 μmol/L. The odds ratio (OR) of subsequent preeclampsia with a value greater than 7.7 μmol/L was 1.59, CI (0.57, 4.43), P = not significant.
In the control group, homocysteine values in the subgroup of 14 women with class A diabetes and in the remaining 54 controls did not show any significant difference (6.63 ± 0.29 and 6.97 ± 0.24 μmol/L, respectively). In the preeclampsia group, homocysteine values did not differ between the subgroup of seven women with class A diabetes and the 27 remaining preeclamptic women (6.6 ± 1.25 and 7.0 ± 1.64 μmol/L, respectively).
In the present study, nonfasting levels of homocysteine were studied and therefore we were not able to exclude a possible effect of dietary factors on homocysteine values.9 Such factors probably did not differ in the present control and preeclampsia groups. The present homocysteine values in healthy pregnant women at 16 weeks' gestation were slightly higher than those recently reported at normal late pregnancy.6 This difference can be explained by a decrease of homocysteine concentrations with advancing gestation.10,11 A similar decrease of homocysteine levels does not occur, however, in women who develop preeclampsia.6 Several factors may increase homocysteine levels in women with preeclampsia. Metabolism in the kidney is the major route by which homocysteine is cleared from plasma12 and this route of elimination may be affected by preeclamptic changes in the kidney. Furthermore, fetoplacental extraction of homocysteine from the maternal circulation may be diminished in preeclampsia13 or there may exist a reduction of vitamin B12, which is essential for the formation of methionine from homocysteine.
Women with class A diabetes have an increased risk of developing preeclampsia.14 In pregnant women with preeclampsia, plasma homocysteine levels were found to be negatively related to insulin sensitivity,6 but a possible relationship between homocysteine metabolism and insulin resistance is not known. In the present study, we did not find any significant change in midtrimester homocysteine levels to be associated with class A diabetes whether women remained normotensive or developed preeclampsia. However, the small size of the subgroups limited the statistical power of these comparisons.
In the present population-based cohort study, we were not able to demonstrate any difference in serum homocysteine levels at 16 weeks' gestation between women who later developed preeclampsia and those who remained normotensive. The elevation of plasma homocysteine level found by other authors in the last trimester in preeclamptic pregnancy could not be observed in the second trimester before the appearance of clinical preeclampsia in the present study. Thus, the present findings failed to confirm any significant changes in homocysteine metabolism preceding the development of preeclampsia. In agreement with the previous findings of Sorensen et al,7 we found a tendency of increase in the risk of developing preeclampsia in women with the highest 25th percentile of values. However, no significant difference in the midtrimester homocysteine levels was found in either study between women who subsequently developed preeclampsia and those who remained normotensive. Thus, homocysteine level does not appear to be a reliable predictive test for clinical use.
1. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407–13.
2. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042–50.
3. Roberts JM, Redman CW. Preeclampsia: More than pregnancy-induced hypertension. Lancet 1993;341:1447–51.
4. Rajkovic A, Catalano PM, Malinow RM. Elevated homocysteine levels with preeclampsia. Obstet Gynecol 1997;90:168–71.
5. Powers RW, Evans RW, Majors AK, Ojimba JI, Ness RB, Crombleholme WR, et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 1998;179:1605–11.
6. Laivuori H, Kaaja R, Turpeinen U, Viinikka L, Ylikorkala O. Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia. Obstet Gynecol 1999;93:489–93.
7. Sorensen TK, Malinow MR, Williams MA, King IB, Luthy DA. Elevated second-trimester serum homocysteine levels and subsequent risk of preeclampsia. Gynecol Obstet Invest 1999;48:98–103.
8. Hietala R, Pohja-Nylander P, Rutanen EM, Laatikainen T. Serum insulin-like growth factor binding protein-1 at 16 weeks and subsequent preeclampsia. Obstet Gynecol 2000;95:185–9.
9. Ueland P, Refsum H, Stabler S, Malinow R, Andersson A, Allen R. Total homocysteine in plasma or serum: Methods and clinical applications. Clin Chem 1993;39:1764–79.
10. Kang SS, Wong PWK, Zhou J, Cook HY. Total homocysteine in plasma and amniotic fluid in pregnant women. Metabolism 1986; 35:889–91.
11. Andersson A, Hulberg B, Brattström L, Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem 1992;30:377–9.
12. Bostom AG, Lathrop L. Homocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997;52:10–20.
13. Malinow MR, Rajkovic A, Duell PG, Hess DL, Upson BM. The relationship between maternal and neonatal umbilical cord plasma homocyst(e)ine suggests a potential role for maternal homocyst(e)ine in fetal metabolism. Am J Obstet Gynecol 119;178:228–33.
14. Suhonen L, Teramo K. Hypertension and preeclampsia in women with gestational glucose intolerance. Acta Obstet Gynecol Scand 1993;72:269–72.